Atlas Trials

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Clinical trial NCT07517640 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07517640
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2026-04-01
Primary completion
2028-02-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.